NVS · Novartis AG
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NVS
this stock
Novartis AG
|
$288.85B | +16.3% | — | — | 0.3% |
|
LLY
ELI LILLY & Co
|
$1.11T | +19.1% | +44.7% | 39.7 | 1.0% |
|
JNJ
Johnson & Johnson
|
$658.89B | +32.1% | +6.0% | 31.8 | 1.1% |
|
ABBV
AbbVie Inc.
|
$457.54B | +16.4% | +8.6% | 73.1 | 1.3% |
|
MRK
Merck & Co., Inc.
|
$335.46B | +44.6% | +1.3% | 108.8 | 1.1% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NVS | +5.3% | +4.7% | -3.1% | +2.7% | +16.3% |
| SPY | -0.4% | +2.9% | +11.6% | +3.0% | +12.8% |
| vs SPY | +5.7% | +1.8% | -14.7% | -0.3% | +3.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.